Clinical Trial Update: Clostridium Butyricum CBM588® vs. Rifaximin for Symptomatic Uncomplicated Diverticular Disease (SUDD): A Real-World Retrospective Study [NA]

View source ↗

Summary

A real-world retrospective study comparing the probiotic Clostridium butyricum CBM588 to rifaximin for Symptomatic Uncomplicated Diverticular Disease (SUDD).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diverticular Disease of the Colon
• Gastrointestinal Disorders

Drugs mentioned

• Clostridium butyricum CBM588 (Clostridium butyricum)
• Rifaximin (rifaximin)

Snippet

Sponsor: Dr. Amjad Khan | Conditions: Diverticular Diseases, Gastro-Intestinal Disorder | NA | Status: COMPLETED